Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis C Virus Gene Therapy - Study results from INSERM in the area of hepatitis C virus gene therapy published
Hepatitis C Virus Gene Therapy Study results from INSERM in the area of hepatitis C virus gene therapy published New research, 'RNAi: a powerful tool to unravel C virus-host interactions within the life cycle,' is the subject of a report. According to

Hepatitis C Virus Epidemiology - Study results from Chiang Mai University, Department of Internal Medicine broaden understanding of hepatitis C virus epidemiology
Hepatitis C Virus Epidemiology Study results from Chiang Mai University, Department of Internal Medicine broaden understanding of hepatitis C virus epidemiology Scientists discuss in 'Occult infection during an in a unit in Thailand' new findings in

Hepatitis C Virus - Research from University of Pittsburgh in the area of hepatitis C virus published
Hepatitis C Virus Research from University of Pittsburgh in the area of hepatitis C virus published Fresh data on are presented in the report 'Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of C .' 'Claudin-1


UPDATES AND COMMENTARY RSS Feed

New Mexico Offers Free Hepatitis C Hotline
Finally being recognized as the widespread, public health problem that it is, the New Mexico Department of Health has taken a giant step forward to help people with Hepatitis C. By launching a new, toll-free phone number, locals concerned about...

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...




Hepatology 1998 Jan;27(1):28-34

Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors.

Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G,
Schepis F, Mandini M, Simoni P, Contin M, Raimondo G

Prolonged Q-T interval predicts severe arrhythmias and sudden death, and has been shown to occur in alcoholic liver disease and cirrhotic patients who are candidates for liver transplantation. This study first evaluated the prevalence of prolonged Q-T interval in a large population of unselected patients with cirrhosis, and assessed the relationship between abnormal Q-T, etiology, and severity of liver disease and mortality of patients. Possible causes of Q-T abnormality were also explored. Ninety-four patients with cirrhosis without overt heart disease and 37 control subjects with mild chronic active hepatitis were enrolled. Rate-corrected Q-T interval (Q-Tc) was assessed along with routine liver tests, Child-Pugh score, serum bile salts, electrolytes and creatinine, plasma renin activity, aldosterone, norepinephrine, atrial natriuretic factor and, gonadal hormones. Q-Tc was longer in patients with cirrhosis than in controls (440.3 +/- 3.2 vs. 393.6 +/- 3.7 ms; P <.001) and prolonged (> 440 ms) in 44 patients (46.8%) and 2 controls (5.4%; P <.001). Q-Tc length was not influenced by the etiology of cirrhosis and correlated with Child-Pugh score (r = .53; P .001), liver tests such as prothrombin activity, and serum concentrations of albumin and bilirubin, plasma bile salts, and plasma norepinephrine. Multivariate analysis showed that only Child-Pugh score and plasma norepinephrine were independently correlated with Q-Tc duration. Over a median follow-up period of 19 months (range, 2-33 months), patients with Q-Tc longer than 440 ms had a significantly lower survival rate than those with normal Q-Tc. Q-T interval is frequently prolonged in patients with cirrhosis, regardless the etiology of the disease, worsens in parallel with the severity of the disease, and may have an important prognostic meaning. In addition to other undefined factors related to the severity of cirrhosis, sympathoadrenergic hyperactivity may play a pathogenetic role.

PMID: 9425913, UI: 98085882

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 13 May 2008